Cargando…

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters

The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5 has rapidly increased in frequency and has become the dominant virus in New England. The bivalent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasrado, Ninaad, Collier, Ai-ris Y., Miller, Jessica, Hachmann, Nicole P., Liu, Jinyan, Sciacca, Michaela, Wu, Cindy, Anand, Trisha, Bondzie, Esther A., Fisher, Jana L., Mazurek, Camille R., Patio, Robert C., Powers, Olivia, Rodrigues, Stefanie L., Rowe, Marjorie, Surve, Nehalee, Ty, Darren M., Korber, Bette, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900747/
https://www.ncbi.nlm.nih.gov/pubmed/36747640
http://dx.doi.org/10.1101/2023.01.22.525079
_version_ 1784882912562249728
author Lasrado, Ninaad
Collier, Ai-ris Y.
Miller, Jessica
Hachmann, Nicole P.
Liu, Jinyan
Sciacca, Michaela
Wu, Cindy
Anand, Trisha
Bondzie, Esther A.
Fisher, Jana L.
Mazurek, Camille R.
Patio, Robert C.
Powers, Olivia
Rodrigues, Stefanie L.
Rowe, Marjorie
Surve, Nehalee
Ty, Darren M.
Korber, Bette
Barouch, Dan H.
author_facet Lasrado, Ninaad
Collier, Ai-ris Y.
Miller, Jessica
Hachmann, Nicole P.
Liu, Jinyan
Sciacca, Michaela
Wu, Cindy
Anand, Trisha
Bondzie, Esther A.
Fisher, Jana L.
Mazurek, Camille R.
Patio, Robert C.
Powers, Olivia
Rodrigues, Stefanie L.
Rowe, Marjorie
Surve, Nehalee
Ty, Darren M.
Korber, Bette
Barouch, Dan H.
author_sort Lasrado, Ninaad
collection PubMed
description The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5 has rapidly increased in frequency and has become the dominant virus in New England. The bivalent mRNA vaccine boosters have been shown to increase neutralizing antibody (NAb) titers to multiple variants, but the durability of these responses remains to be determined. We assessed humoral and cellular immune responses in 30 participants who received the bivalent mRNA boosters and performed assays at baseline prior to boosting, at week 3 after boosting, and at month 3 after boosting. Our data demonstrate that XBB.1.5 substantially escapes NAb responses but not T cell responses after bivalent mRNA boosting. NAb titers to XBB.1 and XBB.1.5 were similar, suggesting that the F486P mutation confers greater transmissibility but not increased immune escape. By month 3, NAb titers to XBB.1 and XBB.1.5 declined essentially to baseline levels prior to boosting, while NAb titers to other variants declined less strikingly.
format Online
Article
Text
id pubmed-9900747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-99007472023-02-07 Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters Lasrado, Ninaad Collier, Ai-ris Y. Miller, Jessica Hachmann, Nicole P. Liu, Jinyan Sciacca, Michaela Wu, Cindy Anand, Trisha Bondzie, Esther A. Fisher, Jana L. Mazurek, Camille R. Patio, Robert C. Powers, Olivia Rodrigues, Stefanie L. Rowe, Marjorie Surve, Nehalee Ty, Darren M. Korber, Bette Barouch, Dan H. bioRxiv Article The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5 has rapidly increased in frequency and has become the dominant virus in New England. The bivalent mRNA vaccine boosters have been shown to increase neutralizing antibody (NAb) titers to multiple variants, but the durability of these responses remains to be determined. We assessed humoral and cellular immune responses in 30 participants who received the bivalent mRNA boosters and performed assays at baseline prior to boosting, at week 3 after boosting, and at month 3 after boosting. Our data demonstrate that XBB.1.5 substantially escapes NAb responses but not T cell responses after bivalent mRNA boosting. NAb titers to XBB.1 and XBB.1.5 were similar, suggesting that the F486P mutation confers greater transmissibility but not increased immune escape. By month 3, NAb titers to XBB.1 and XBB.1.5 declined essentially to baseline levels prior to boosting, while NAb titers to other variants declined less strikingly. Cold Spring Harbor Laboratory 2023-01-23 /pmc/articles/PMC9900747/ /pubmed/36747640 http://dx.doi.org/10.1101/2023.01.22.525079 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Lasrado, Ninaad
Collier, Ai-ris Y.
Miller, Jessica
Hachmann, Nicole P.
Liu, Jinyan
Sciacca, Michaela
Wu, Cindy
Anand, Trisha
Bondzie, Esther A.
Fisher, Jana L.
Mazurek, Camille R.
Patio, Robert C.
Powers, Olivia
Rodrigues, Stefanie L.
Rowe, Marjorie
Surve, Nehalee
Ty, Darren M.
Korber, Bette
Barouch, Dan H.
Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
title Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
title_full Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
title_fullStr Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
title_full_unstemmed Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
title_short Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
title_sort waning immunity against xbb.1.5 following bivalent mrna boosters
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900747/
https://www.ncbi.nlm.nih.gov/pubmed/36747640
http://dx.doi.org/10.1101/2023.01.22.525079
work_keys_str_mv AT lasradoninaad waningimmunityagainstxbb15followingbivalentmrnaboosters
AT collierairisy waningimmunityagainstxbb15followingbivalentmrnaboosters
AT millerjessica waningimmunityagainstxbb15followingbivalentmrnaboosters
AT hachmannnicolep waningimmunityagainstxbb15followingbivalentmrnaboosters
AT liujinyan waningimmunityagainstxbb15followingbivalentmrnaboosters
AT sciaccamichaela waningimmunityagainstxbb15followingbivalentmrnaboosters
AT wucindy waningimmunityagainstxbb15followingbivalentmrnaboosters
AT anandtrisha waningimmunityagainstxbb15followingbivalentmrnaboosters
AT bondzieesthera waningimmunityagainstxbb15followingbivalentmrnaboosters
AT fisherjanal waningimmunityagainstxbb15followingbivalentmrnaboosters
AT mazurekcamiller waningimmunityagainstxbb15followingbivalentmrnaboosters
AT patiorobertc waningimmunityagainstxbb15followingbivalentmrnaboosters
AT powersolivia waningimmunityagainstxbb15followingbivalentmrnaboosters
AT rodriguesstefaniel waningimmunityagainstxbb15followingbivalentmrnaboosters
AT rowemarjorie waningimmunityagainstxbb15followingbivalentmrnaboosters
AT survenehalee waningimmunityagainstxbb15followingbivalentmrnaboosters
AT tydarrenm waningimmunityagainstxbb15followingbivalentmrnaboosters
AT korberbette waningimmunityagainstxbb15followingbivalentmrnaboosters
AT barouchdanh waningimmunityagainstxbb15followingbivalentmrnaboosters